Theseus Pharmaceuticals

NEWS
Theseus Pharmaceuticals was acquired by Cocentra Biosciences, LLC in 2024.
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Companies across the biotech and biopharma industries recently reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine.
This morning, multiple companies announced hundreds of millions of dollars were raised in Series B rounds that will be used to advance therapeutics and business development programs.
IN THE PRESS
Theseus Pharmaceuticals, Inc. today announced that Concentra Biosciences, LLC (“Concentra”) through its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4.05 in cash.
As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered into a merger agreement (the “Merger Agreement”) with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) (“Theseus”) whereby Purchaser will acquire Theseus for a price per share of Theseus common stock.
Theseus Pharmaceuticals, Inc. today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC (“Concentra”) will acquire Theseus for a price per share of Theseus common stock.
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC.
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced that the company will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14 at 9:45 a.m. ET.
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the second quarter ended June 30, 2023.
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced that it is discontinuing enrollment in the ongoing phase 1/2 study and terminating development of THE-630 in patients with gastrointestinal stromal tumors (GIST).
Theseus Pharmaceuticals, Inc. announced that the company will participate in a live Fireside Chat at the Jefferies Healthcare Conference on June 8th at 10:30am ET.
Theseus Pharmaceuticals, Inc. announced initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced gastrointestinal stromal tumors.
Theseus Pharmaceuticals, Inc. today announced business highlights and reported financial results for the first quarter ended March 31, 2023.